跳至主要内容
临床试验/NCT01106989
NCT01106989已完成2 期

An Open-label Pilot Study Evaluating Synera® in the Treatment of Patients With Pain Associated With Myofascial Trigger Points

ZARS Pharma Inc.1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2010年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
20
试验地点
1
主要终点
Pain intensity

研究概览

简要总结

The purpose of this pilot study is to explore the potential usefulness of a heated lidocaine 70 mg and tetracaine 70 mg topical patch for the treatment of pain associated with myofascial trigger points.

详细描述

The purpose of this pilot study is to explore the usefulness of a heated lidocaine 70 mg and tetracaine 70 mg topical patch for the treatment of pain associated with myofascial trigger points. The study will consist of a 2-week, open-label treatment period followed by a 2 week follow-up period conducted at a single study site. Eligible patients must have a clinical diagnosis of pain (minimum 1-month duration) associated with up to 3 identifiable myofascial trigger points. A number of efficacy variables will be employed to evaluate their utility for assessing painful responses in this population.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • be at least 18 years of age
  • have a clinical diagnosis of pain (minimum 1-month duration) associated with up to 3 myofascial trigger points
  • have trigger points confined to the upper back, shoulder, and neck

排除标准

  • have used any topically applied pain medication on the target treatment area within 3 days preceding the Screening/Baseline Visit
  • have used any topically applied pain medication on the target treatment area within 3 days preceding the Screening/Baseline Visit
  • have used any injected pain medication with 28 days preceding the Screening/Baseline Visit
  • are receiving class 1 antiarrhythmic drugs (ie, tocainide, mexiletine, etc.)
  • Other protocol-defined inclusion/exclusion criteria may apply.

研究组 & 干预措施

Heated lidocaine/tetracaine patch

Experimental

Active

干预措施: Heated lidocaine/tetracaine patch (Drug)

结局指标

主要结局

Pain intensity

时间窗: Two weeks

次要结局

  • Pain interference with activities (eg, general, normal work, sleep)(Two weeks)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验